Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1162-1172

  Cai, Yun ^a   Wang, Rui ^a   Liang, Beibei ^a   Bai, Nan ^a   Liu, Youning ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFTRIAXONE; CILASTATIN PLUS IMIPENEM; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CHILL; COCHRANE LIBRARY; COMMUNITY ACQUIRED PNEUMONIA; COMPLICATED INTRAABDOMINAL INFECTION; COMPLICATED SKIN AND SKIN STRUCTURE INFECTION; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EMBASE; ENTEROCOCCAL INFECTION; FEVER; HEADACHE; HIGH RISK POPULATION; HUMAN; INFECTION; MEDLINE; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; NAUSEA; PAIN; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEPSIS; SKIN INFECTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VANCOMYCIN RESISTANT ENTEROCOCCUS INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASES; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MINOCYCLINE; SKIN DISEASES, BACTERIAL; VANCOMYCIN;

EID: 79952325057     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01402-10     Document Type: Article

References (49)

1. Anthony, K. B., et al. 2008. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46:567-570.
2. Babinchak, T., et al. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl. 5):S354-S367.
3. Bergallo, C., et al. 2009. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn. Microbiol. Infect. Dis. 63:52-61.
4. Bergeron, J., et al. 1996. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection. Antimicrob. Agents Chemother. 40:2226-2228.
5. Bhattacharya, M., A. Parakh, and M. Narang. 2009. Tigecycline. J. Postgrad. Med. 55:65-68.
6. Breedt, J., et al. 2005. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob. Agents Chemother. 49:4658-4666.
7. Chen, Z., et al. 2010. Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect. Dis. 10:217.
8. Cobo, J., et al. 2008. Use of tigecycline for the treatment of prolonged bacteremia due to a multiresistant VIM-1 and SHV-12 beta-lactamase-producing Klebsiella pneumoniae epidemic clone. Diagn. Microbiol. Infect. Dis. 60:319-322.
9. Cui, J. C., Y. N. Liu, and L. A. Chen. 2010. Mutant prevention concentration of tigecycline for carbapenem-susceptible and -resistant Acinetobacter baumannii. J. Antibiot. (Tokyo) 63:29-31.
10. Curcio, D., F. Fernandez, J. Vergara, W. Vazquez, and C. M. Luna. 2009. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J. Chemother. 21:58-62.
11. Daly, M. W., D. J. Riddle, N. A. Ledeboer, W. M. Dunne, and D. J. Ritchie. 2007. Tigecycline for treatment of pneumonia and empyema caused by carbapenemase-producing Klebsiella pneumoniae. Pharmacotherapy 27:1052-1057.
12. Dartois, N., N. Castaing, H. Gandjini, A. Cooper, and G. Tigecycline 313 Study. 2008. Tigecycline versus levofloxacin for the treatment of community-acquired pneumonia: European experience. J. Chemother. 20(Suppl. 1):28-35.
13. Doan, T. L., H. B. Fung, D. Mehta, and P. F. Riska. 2006. Tigecycline: a glycylcycline antimicrobial agent. Clin. Ther. 28:1079-1106.
14. Evagelopoulou, P., P. Myrianthefs, A. Markogiannakis, G. Baltopoulos, and A. Tsakris. 2008. Multidrug-resistant Klebsiella pneumoniae mediastinitis safely and effectively treated with prolonged administration of tigecycline. Clin. Infect. Dis. 46:1932-1933.
15. FDA. 2010. Drug safety announcement-tigecycline. FDA, Rockville, MD. http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed 1 September 2010.
16. Florescu, I., et al. 2008. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J. Antimicrob. Chemother. 62(Suppl. 1):i17-i28.
17. Fomin, P., et al. 2008. The efficacy and safety of tigecycline for the treatment of complicated intra-adominal infections - the European experience. J. Chemother. 20:12-19.
18. Gardiner, D., G. Dukart, A. Cooper, and T. Babinchak. 2010. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin. Infect. Dis. 50:229-238.
19. Gilson, M., et al. 2008. Acute pancreatitis related to tigecycline: case report and review of the literature. Scand. J. Infect. Dis. 40:681-683.
20. Grolman, D. C. 2007. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections. Int. J. Infect. Dis. 11:S7-S15.
21. Herpers, B. L., et al. 2009. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin. Infect. Dis. 48:1732-1735.
22. Higgins, J., S. Thompson, J. Deeks, and D. Altman. 2002. Statistical heterogeneity in systematic reviews of clinical trials: a critical appraisal of guidelines and practice. J. Health Serv. Res. Policy 7:51-61.
23. Hung, W. Y., L. Kogelman, G. Volpe, M. Iafrati, and L. Davidson. 2009. Tigecycline-induced acute pancreatitis: case report and literature review. Int. J. Antimicrob. Agents 34:486-489.
24. Jadad, A. R., et al. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17:1-12. (Pubitemid 26120810)
25. Jenkins, I. 2007. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J. Hosp. Med. 2:343-344.
26. Kasbekar, N. 2006. Tigecycline: a new glycylcycline antimicrobial agent. Am. J. Health Syst. Pharm. 63:1235-1243.
27. Khanna, N., and T. Inkster. 2008. Meticillin-resistant Staphylococcus aureus hepatic abscess treated with tigecycline. J. Clin. Pathol. 61:967-968.
28. Krueger, W. A., et al. 2008. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli. J. Clin. Microbiol. 46:817-820.
29. Munoz-Price, L. S., K. Lolans, and J. P. Quinn. 2006. Four cases of invasive methicillin-resistant Staphylococcus aureus (MRSA) infections treated with tigecycline. Scand. J. Infect. Dis. 38:1081-1084.
30. Oliva, M. E., et al. 2005. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID numbers: 3074A1-301-WW; ClinicalTrials.gov identifier: NCT00081744]. BMC Infect. Dis. 5:88.
31. Passarell, J., et al. 2009. Exposure-response analyses of tigecycline tolerability in healthy subjects. Diagn. Microbiol. Infect. Dis. 65:123-129.
32. Peterson, L. R. 2008. A review of tigecycline-the first glycylcycline. Int. J. Antimicrob. Agents 32(Suppl. 4):S215-S222.
33. Reid, G. E., S. A. Grim, C. A. Aldeza, W. M. Janda, and N. M. Clark. 2007. Rapid development of Acinetobacter baumannii resistance to tigecycline. Pharmacotherapy 27:1198-1201.
34. Rello, J. 2005. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline. J. Chemother. 17:12-22. (Pubitemid 41686777)
35. Sacchidanand, S., et al. 2005. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int. J. Infect. Dis. 9:251-261.
36. Scheetz, M. H., et al. 2006. Peritoneal fluid penetration of tigecycline. Ann. Pharmacother. 40:2064-2067.
37. Sopirala, M. M., et al. 2008. Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients. J. Heart Lung Transplant. 27:804-807.
38. Stanzani, M., et al. 2007. Successful treatment of multi-resistant Pseudomonas aeruginosa osteomyelitis after allogeneic bone marrow transplantation with a combination of colistin and tigecycline. J. Med. Microbiol. 56:1692-1695.
39. Sterne, J. A., and M. Egger. 2001. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J. Clin. Epidemiol. 54:1046-1055.
40. Stumpf, A. N., C. Schmidt, W. Hiddemann, and A. Gerbitz. 2009. High serum concentrations of cyclosporin related to administration of tigecycline. Eur. J. Clin. Pharmacol. 65:101-103.
41. Taccone, F. S., et al. 2006. Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur. J. Clin. Microbiol. Infect. Dis. 25:257-260.
42. Tanaseanu, C., et al. 2008. Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn. Microbiol. Infect. Dis. 61:329-338.
43. Tanaseanu, C., et al. 2009. Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia. BMC Pulm. Med. 9:44.
44. Teras, J., et al. 2008. Overview of tigecycline efficacy and safety in the treatment of complicated skin and skin structure infections - a European perspective. J. Chemother. 20(Suppl. 1):20-27.
45. Towfigh, S., J. Pasternak, A. Poirier, H. Leister, and T. Babinchak. 2010. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin. Microbiol. Infect. 16:1274-1281.
46. Vasilev, K., et al. 2008. A phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J. Antimicrob. Chemother. 62(Suppl. 1):i29-i40.
47. Wadi, J. A., and M. A. Al Rub. 2007. Multidrug resistant Acinetobacter nosocomial meningitis treated successfully with parenteral tigecycline. Ann. Saudi Med. 27:456-458.
48. Wadi, J. A., and F. Selawi. 2009. Extended-spectrum beta-lactamase Klebsiella pneumoniae meningitis treated with tigecycline. Ann. Saudi Med. 29:239-240.
49. Woodhead, M., et al. 2005. Guidelines for the management of adult lower respiratory tract infections. Eur. Respir. J. 26:1138-1180.